SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPorvair Regulatory News (PRV)

Share Price Information for Porvair (PRV)

Share Price is delayed by 15 minutes
Get Live Data
830.00    14.00 (1.72%)
Bid:
824.00
Ask:
828.00
Spread: 4.00 (0.485%)
Market Cap: £382.60m
PRV Live PriceLast checked at - London Stock Exchange

Intraday Porvair Share Chart

Trading Update and Covid-19 Statement

8 Apr 2020 07:00

RNS Number : 1263J
Porvair PLC
08 April 2020
 

For immediate release 8 April 2020

 

Porvair plc

("Porvair" or the "Group")

 

Trading Update and Covid-19 Statement

Porvair plc ("Porvair" or "the Group"), the specialist filtration and environmental technology group, today issues a trading update and comment on COVID-19.

The overriding priority for Porvair management teams over the last few weeks has been the wellbeing of staff and their families. Health and safety guidelines for each country are being followed and physical distancing at work is being observed. Staff in China remained on full pay throughout a seven week shut-down and are now all back at work. Where staff members elsewhere in the Group have needed to self-isolate similar arrangements have been made.

Porvair is doing what it can to help governments and health services. We are supplying filter components for several of the consortia now building ventilator and breathing apparatus: one in France; one in Sweden; three in the US; and the Mercedes AMG/Formula 1 consortium in the UK. Porvair is supplying consumables for dozens of US testing laboratories, including the Mayo Clinic; is producing millions of pipette tips for COVID-19 testing kits; and thousands of filters for Diagnostics in the Real World. Shifts have been added to produce chromatography bed supports and pharmaceutical grade water filters. The Board anticipates further programmes will emerge as the crisis continues. Whilst these orders are relatively small they illustrate the capabilities and commitment of our staff.

In financial terms, the impact on the Group will depend on the duration of the COVID-19 pandemic and on the severity of its economic consequences. The Board of Porvair has considered various outlook scenarios, stress testing the Group for different levels of challenge, plant by plant. The Group has a strong balance sheet and is expected to be both profitable and modestly cash generative through the balance of the year in all but the most pessimistic scenarios. The Board does not believe it needs to change its final dividend recommendation.

In its outlook statement dated 31 January 2020 the Group noted its positive exposure to global growth trends including tighter environmental regulations; growth in analytical science; the expansion of air travel; the replacement of plastic by aluminium and the drive for manufacturing process efficiency. Looking to 2021 and beyond the Group expects these trends to continue. Indeed, 2020 has started well with revenues ahead of the prior year in the four months to the end of March. All plants are currently open and April is busy. However, there will no doubt be disruption during the rest of the year. Demand, in sectors including aviation, automotive and industrial manufacturing, is likely to decline. Other sectors, mainly in the Laboratory division, are expected to remain busy. As we wait to see how the economic consequences of COVID 19 develop, the Board therefore considers it prudent to withdraw guidance until the outlook is more certain.

Should the situation change significantly, the Group will issue a further update at its AGM on 21 April 2020.

For further information, please contact:

Porvair plc

 

01553 765 500

Ben Stocks, Group Chief Executive

Chris Tyler, Group Finance Director

 

 

Buchanan Communications

 

0207 466 5000

Charles Ryland / Steph Watson

 

 

 

Notes to editors

 

Porvair plc

Porvair is a group of specialist filtration and environmental technology businesses. Its businesses design and manufacture a range of bespoke consumable filtration products that are used in a range of niche filtration markets. It operates in three divisions: Aerospace & Industrial; Laboratory; and Metal Melt Quality.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAKLXESLEEFA
Date   Source Headline
14th Feb 201812:02 pmRNSPrice Monitoring Extension
13th Feb 20184:40 pmRNSSecond Price Monitoring Extn
13th Feb 20184:35 pmRNSPrice Monitoring Extension
1st Feb 20185:57 pmRNSBlock listing Interim Review
29th Jan 20187:00 amRNSResults for the year ended 30 November 2017
2nd Jan 201810:35 amRNSHolding(s) in Company
12th Dec 20174:52 pmRNSHolding(s) in Company
8th Dec 20177:00 amRNSPre-close Trading Update and Acquisition
6th Nov 20174:40 pmRNSSecond Price Monitoring Extn
6th Nov 20174:35 pmRNSPrice Monitoring Extension
18th Oct 20174:35 pmRNSPrice Monitoring Extension
13th Oct 201710:00 amRNSDirector's Shareholding and Issue of Equity
10th Oct 20178:27 amRNSHolding(s) in Company
3rd Oct 20174:35 pmRNSPrice Monitoring Extension
28th Sep 20177:00 amRNSAppointment of an Independent NED
19th Sep 20177:00 amRNSTrading Update
17th Aug 201711:34 amRNSHolding(s) in Company
28th Jun 201712:32 pmRNSDirector's Shareholding and Issue of Equity
27th Jun 20177:00 amRNSHalf Yearly Results
22nd Jun 201710:00 amRNSAdditional Listing
5th Jun 20177:00 amRNSTrading Update
11th Apr 201711:50 amRNSAGM resolutions
11th Apr 20177:00 amRNSAGM Statement and Trading Update
10th Apr 20174:51 pmRNSHolding(s) in Company
5th Apr 20177:00 amRNSAcquisition
24th Mar 20178:00 amRNSDirector's Shareholding and Issue of Equity
10th Mar 201712:05 pmRNSPosting of Accounts, AGM and Change of Auditor
22nd Feb 201710:33 amRNSHolding(s) in Company
30th Jan 20177:00 amRNSResults for the year ended 30 November 2016
26th Jan 20174:12 pmRNSHolding(s) in Company
6th Dec 20167:00 amRNSTrading Update and Directorate Change
30th Nov 20168:21 amRNSDirector's shareholding and changes in equity
14th Nov 201610:28 amRNSDr Krishnamurthy Rajagopal
10th Nov 20165:09 pmRNSHolding(s) in Company
3rd Oct 20164:06 pmRNSHolding(s) in Company
3rd Oct 20164:04 pmRNSHolding(s) in Company
3rd Oct 201610:29 amRNSHolding(s) in Company
21st Sep 201612:07 pmRNSSecond Price Monitoring Extn
21st Sep 201612:02 pmRNSPrice Monitoring Extension
21st Sep 20169:28 amRNSHolding(s) in Company
21st Sep 20167:00 amRNSTrading update & appointment of an Independent NED
27th Jun 20167:00 amRNSHalf yearly results
16th Jun 20163:49 pmRNSHolding(s) in Company
16th Jun 20163:48 pmRNSHolding(s) in Company
16th Jun 201611:02 amRNSHolding(s) in Company
2nd Jun 20167:00 amRNSTrading Update
17th May 20163:19 pmRNSHolding(s) in Company
17th May 20163:18 pmRNSHolding(s) in Company
12th Apr 20162:51 pmRNSAGM resolutions
18th Mar 201612:45 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.